Intellia Therapeutics (NTLA) Tops Q1 EPS by 17c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.10), $0.17 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $16.63 million versus the consensus estimate of $12.79 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Argo Graphene raises private placement target to $1.5M
- Goldgroup Mining launches $75M private placement with $60M committed
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
